Phathom Pharmaceuticals annual gross margin
2023
2024
2025
Phathom Pharmaceuticals's gross margin was 87.09% for fiscal 2025.
View full Phathom Pharmaceuticals company overview| Fiscal year | Period ended | Gross margin | Change (percentage points) |
|---|---|---|---|
| 2025 | 2025-12-31 | 87.09% | +1.52 pp |
| 2024 | 2024-12-31 | 85.57% | +10.06 pp |
| 2023 | 2023-12-31 | 75.51% | — |
| Fiscal quarter | Period ended | Gross margin | Change (percentage points) |
|---|---|---|---|
| Q2 2026 | 2026-06-30 | 79.68% | −7.57 pp |
| Q1 2026 | 2026-03-31 | 79.42% | −7.52 pp |
| Q4 2025 | 2025-12-31 | 86.72% | −0.42 pp |
| Q3 2025 | 2025-09-30 | 87.50% | +1.90 pp |
| Q2 2025 | 2025-06-30 | 87.25% | +6.03 pp |
| Q1 2025 | 2025-03-31 | 86.94% | +9.22 pp |
| Q4 2024 | 2024-12-31 | 87.14% | +11.63 pp |
| Q3 2024 | 2024-09-30 | 85.59% | — |
| Q2 2024 | 2024-06-30 | 81.21% | — |
| Q1 2024 | 2024-03-31 | 77.72% | — |
| Q4 2023 | 2023-12-31 | 75.51% | — |
Across the available reported history, Phathom Pharmaceuticals's gross margin increased from 85.57% to 87.09%, a change of +1.52 percentage points. The latest reported quarter, Q2 2026, shows 79.68%.
Gross margin measures the percentage of revenue remaining after the direct costs of producing goods or services. It helps show how efficiently a company turns sales into gross profit before operating expenses.
TickerStat calculates gross margin as SEC-reported gross profit divided by SEC-reported revenue for the same fiscal period. Changes are shown in percentage points. Fiscal periods can differ from calendar years, so exact period-end dates are included.
Review Phathom Pharmaceuticals filings at SEC.gov ↗